| pubmed-article:2292331 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:2292331 | lifeskim:mentions | umls-concept:C0003873 | lld:lifeskim |
| pubmed-article:2292331 | lifeskim:mentions | umls-concept:C0087111 | lld:lifeskim |
| pubmed-article:2292331 | lifeskim:mentions | umls-concept:C0086343 | lld:lifeskim |
| pubmed-article:2292331 | lifeskim:mentions | umls-concept:C2603343 | lld:lifeskim |
| pubmed-article:2292331 | lifeskim:mentions | umls-concept:C0076096 | lld:lifeskim |
| pubmed-article:2292331 | pubmed:issue | 6 | lld:pubmed |
| pubmed-article:2292331 | pubmed:dateCreated | 1991-4-9 | lld:pubmed |
| pubmed-article:2292331 | pubmed:abstractText | A study was undertaken to investigate the efficacy and tolerability of 20 mg/day tenoxicam given orally for 12 weeks in a general practice setting in a broad range of patients suffering from osteo-arthritis or rheumatoid arthritis. The group of 2963 patients was recruited from 252 general practices. Some patients (60%) continued treatment into the long-term phase of the trial, beyond 12 weeks, whereas other patients (31%) elected to continue treatment beyond 52 weeks. There was a reduction in the number of patients recording pain and stiffness over the course of the study. Adverse events were typical of a nonsteroidal anti-inflammatory drug with no unexpected or unusual side-effects. It is concluded that tenoxicam can be recommended for use in osteo-arthritis and rheumatoid arthritis. | lld:pubmed |
| pubmed-article:2292331 | pubmed:language | eng | lld:pubmed |
| pubmed-article:2292331 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2292331 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:2292331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2292331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2292331 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:2292331 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:2292331 | pubmed:issn | 0300-0605 | lld:pubmed |
| pubmed-article:2292331 | pubmed:author | pubmed-author:HillS ASA | lld:pubmed |
| pubmed-article:2292331 | pubmed:author | pubmed-author:JamiesonVV | lld:pubmed |
| pubmed-article:2292331 | pubmed:author | pubmed-author:SpenceSS | lld:pubmed |
| pubmed-article:2292331 | pubmed:author | pubmed-author:LangdonC GCG | lld:pubmed |
| pubmed-article:2292331 | pubmed:author | pubmed-author:MoranD GDG | lld:pubmed |
| pubmed-article:2292331 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:2292331 | pubmed:volume | 18 | lld:pubmed |
| pubmed-article:2292331 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:2292331 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:2292331 | pubmed:pagination | 489-96 | lld:pubmed |
| pubmed-article:2292331 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:meshHeading | pubmed-meshheading:2292331-... | lld:pubmed |
| pubmed-article:2292331 | pubmed:articleTitle | A multicentre study of tenoxicam for the treatment of osteo-arthritis and rheumatoid arthritis in general practice. | lld:pubmed |
| pubmed-article:2292331 | pubmed:affiliation | Symons Medical Centre, Maidenhead, UK. | lld:pubmed |
| pubmed-article:2292331 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:2292331 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:2292331 | pubmed:publicationType | Multicenter Study | lld:pubmed |
